Merkel cell carcinoma update: the case for two tumours

被引:22
作者
Nirenberg, A. [1 ]
Steinman, H. [2 ,3 ]
Dixon, J. [4 ]
Dixon, A. [1 ,5 ]
机构
[1] Australasian Coll Cutaneous Oncol, Docklands, Vic, Australia
[2] Campbell Univ, Sch Osteopath Med, Lillington, NC USA
[3] US Dermatol Partners, Grapevine, TX USA
[4] Baker Heart & Diabet Inst, Melbourne, Vic, Australia
[5] Amer Osteopath Coll Dermatol, Kirskville, MO USA
关键词
POLYOMAVIRUS INFECTION; PD-1; BLOCKADE; SURVIVAL; ASSOCIATION; EXPRESSION; DIFFERENTIATION; EPIDEMIOLOGY; ORIGIN;
D O I
10.1111/jdv.16158
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Merkel cell carcinoma (MCC) is an aggressive tumour with neuroendocrine differentiation. Clinically significant differences within the entity we know as MCC are apparent. This review aims to evaluate the evidence for differences in tumours within Merkel cell carcinoma and to stratify these. A literature search of research pertaining to various characteristics MCC was undertaken from 1972, when Merkel cell carcinoma was first described, to 2018, using PubMed and similar search engines. A total of 41 papers were analysed, including clinical trials, laboratory-based research and reviews. A proportion of MCC has Merkel cell polyomavirus genome integrated (MCPyV+) while others do not (MCPyV-). Both types have a different mutation burden. MCPyV+ tumours are likely true neuroendocrine carcinomas, with a dermal origin, probably from fibroblasts which have been transformed by integration of the viral genome. MCPyV-tumours are likely derived from either keratinocytes or epidermal stem cells, are probably squamous cell carcinomas with neuroendocrine differentiation, and are related to sun damage. Prognostic factors (apart from tumour stage) include the MCPyV status, with MCPyV+ tumours having a better prognosis. P63 expression confers a worse prognosis in most studies. CD8+ lymphocytes play an important role, providing a possible target for PD1/PD-L1 blockade treatment. The incidence of MCC varies from country to country. Countries such as Australia have a high rate and a far greater proportion of MCPyV- tumours than places such as the United Kingdom. MCC doubtlessly encompasses two tumours. The two tumours have demonstrated differences in prognosis and management. One is a neuroendocrine carcinoma related to MCPyV integration likely derived from fibroblasts, and the other is a UV-related squamous cell carcinoma with neuroendocrine differentiation, presumptively derived from either keratinocytes or epidermal stem cells. We propose naming the former Merkel type sarcoma and the latter squamous cell carcinoma, Merkel type.
引用
收藏
页码:1425 / 1431
页数:7
相关论文
共 41 条
  • [11] Merkel Cell Polyomavirus-Infected Merkel Cell Carcinoma Cells Require Expression of Viral T Antigens
    Houben, Roland
    Shuda, Masahiro
    Weinkam, Rita
    Schrama, David
    Feng, Huichen
    Chang, Yuan
    Moore, Patrick S.
    Becker, Juergen C.
    [J]. JOURNAL OF VIROLOGY, 2010, 84 (14) : 7064 - 7072
  • [12] Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
    Kaufman, Howard L.
    Russell, Jeffery
    Hamid, Omid
    Bhatia, Shailender
    Terheyden, Patrick
    D'Angelo, Sandra P.
    Shih, Kent C.
    Lebbe, Celeste
    Linette, Gerald P.
    Milella, Michele
    Brownell, Isaac
    Lewis, Karl D.
    Lorch, Jochen H.
    Chin, Kevin
    Mahnke, Lisa
    von Heydebreck, Anja
    Cuillerot, Jean-Marie
    Nghiem, Paul
    [J]. LANCET ONCOLOGY, 2016, 17 (10) : 1374 - 1385
  • [13] Association of merkel cell polyomavirus infection with morphologic differences in merkel cell carcinoma
    Kuwamoto, Satoshi
    Higaki, Hiromi
    Kanai, Kyosuke
    Iwasaki, Takeshi
    Sano, Hitoshi
    Nagata, Keiko
    Kato, Kaoru
    Kato, Masako
    Murakami, Ichiro
    Horie, Yasushi
    Yamamoto, Osamu
    Hayashi, Kazuhiko
    [J]. HUMAN PATHOLOGY, 2011, 42 (05) : 632 - 640
  • [14] Increasing Tumor Thickness is Associated with Recurrence and Poorer Survival in Patients with Merkel Cell Carcinoma
    Lim, Cathy S.
    Whalley, Deborah
    Haydu, Lauren E.
    Murali, Rajmohan
    Tippett, Jill
    Thompson, John F.
    Hruby, George
    Scolyer, Richard A.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (11) : 3325 - 3334
  • [15] PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival
    Lipson, Evan J.
    Vincent, Jeremy G.
    Loyo, Myriam
    Kagohara, Luciane T.
    Luber, Brandon S.
    Wang, Hao
    Xu, Haiying
    Nayar, Suresh K.
    Wang, Timothy S.
    Sidransky, David
    Anders, Robert A.
    Topalian, Suzanne L.
    Taube, Janis M.
    [J]. CANCER IMMUNOLOGY RESEARCH, 2013, 1 (01) : 54 - 63
  • [16] Identifying the Target Cells and Mechanisms of Merkel Cell Polyomavirus Infection
    Liu, Wei
    Yang, Ruifeng
    Payne, Aimee S.
    Schowalter, Rachel M.
    Spurgeon, Megan E.
    Lambert, Paul F.
    Xu, Xiaowei
    Buck, Christopher B.
    You, Jianxin
    [J]. CELL HOST & MICROBE, 2016, 19 (06) : 775 - 787
  • [17] Merkel cell carcinoma with divergent differentiation: histopathological and immunohistochemical study of 15 cases with PCR analysis for Merkel cell polyomavirus
    Martin, Blanca
    Poblet, Enrique
    Jose Rios, Juan
    Kazakov, Dmitry
    Kutzner, Heinz
    Brenn, Thomas
    Calonje, Eduardo
    [J]. HISTOPATHOLOGY, 2013, 62 (05) : 711 - 722
  • [18] Polyomavirus-Negative Merkel Cell Carcinoma: A More Aggressive Subtype Based on Analysis of 282 Cases Using Multimodal Tumor Virus Detection
    Moshiri, Ata S.
    Doumani, Ryan
    Yelistratova, Lola
    Blom, Astrid
    Lachance, Kristina
    Shinohara, Michi M.
    Delaney, Martha
    Chang, Oliver
    McArdle, Susan
    Thomas, Hannah
    Asgari, Maryam M.
    Huang, Meei-Li
    Schwartz, Stephen M.
    Nghiem, Paul
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (04) : 819 - 827
  • [19] Immunoglobulin Expressions Are Only Associated With MCPyV-positive Merkel Cell Carcinomas But Not With MCPyV-negative Ones Comparison of Prognosis
    Murakami, Ichiro
    Takata, Katsuyoshi
    Matsushita, Michiko
    Nonaka, Daisuke
    Iwasaki, Takeshi
    Kuwamoto, Satoshi
    Kato, Masako
    Mohri, Takashi
    Nagata, Keiko
    Kitamura, Yukisato
    Yoshino, Tadashi
    Hayashi, Kazuhiko
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2014, 38 (12) : 1627 - 1635
  • [20] PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
    Nghiem, Paul T.
    Bhatia, Shailender
    Lipson, Evan J.
    Kudchadkar, Ragini R.
    Miller, Natalie J.
    Annamalai, Lakshmanan
    Berry, Sneha
    Chartash, Elliot K.
    Daud, Adil
    Fling, Steven P.
    Friedlander, Philip A.
    Kluger, Harriet M.
    Kohrt, Holbrook E.
    Lundgren, Lisa
    Margolin, Kim
    Mitchell, Alan
    Olencki, Thomas
    Pardoll, Drew M.
    Reddy, Sunil A.
    Shantha, Erica M.
    Sharfman, William H.
    Sharon, Elad
    Shemanski, Lynn R.
    Shinohara, Michi M.
    Sunshine, Joel C.
    Taube, Janis M.
    Thompson, John A.
    Townson, Steven M.
    Yearley, Jennifer H.
    Topalian, Suzanne L.
    Cheever, Martin A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (26) : 2542 - 2552